Afya (NASDAQ: AFYA)

$13.84+3.21%today

Brazilian ADR trading on the NASDAQ, priced in US dollars.

Display currency

Market Cap, EPS and the financial totals below — switch between US dollars and BRL.

Market Cap: $1.27B
P/E (TTM): 8.3x
P/B: 1.3x
EPS (TTM): $1.67
Dividend Yield: 4.74%
52-Week Range: $13.00 – $16.50
Volume: 168K
Previous Close: $13.41

TTM = trailing twelve months — the most recent 12 months (a rolling window), used for P/E, EPS and dividends. On the tables and charts below, the in-progress current year appears as a “Last 12M” column labelled with the quarter range it covers.

Performance

Today

+3.21%

1 Week

+2.98%

1 Month

-0.43%

YTD

-10.19%

1 Year

-8.10%

5 Years

-32.06%

About Afya

US Ticker: AFYA
B3 Ticker: —
Exchange: NASDAQ
Currency: USD
Sector: Consumer Defensive
Industry: Education & Training Services
Headquarters: Belo Horizonte, MG, Brazil
Employees: 9,395
CEO: Mr. Virgílio Deloy Capobianco Gibbon
Founded: 1999

Afya Limited operates as a medical education group in Brazil.

The company operates in three segments: Undergraduate, Continuing Education, and Medical Practice Solutions.

The Undergraduate segment offers educational services through undergraduate courses related to medical school, health sciences, and other non-health undergraduate programs, including medicine, dentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicine, business administration, accounting, law, civil and industrial engineering, and pedagogy.

The Continuing Education segment provides medical education, including residency preparation programs, specialization test preparation, graduate courses in medicine, and digital and in-person professional development for physicians and medical students.

The Medical Practice Solutions segment offers clinical decision support platforms, medical practice management software, healthcare financial services, and digital healthcare ecosystem solutions, such as electronic medical records, practice management tools, telemedicine, digital prescriptions, and doctor-patient relationship platforms.

This segment also provides a subscription-based mobile app and website portal that focuses on assisting health professionals and students with clinical decision-making through tools, such as medical calculators, charts, and updated content, as well as prescriptions, clinical scores, medical procedures and laboratory exams, and others.

The company also offers educational health and medical imaging; and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

In addition, it offers printed and digital content, as well as an online medical education platform and physicians, healthcare professionals and students.

Afya Limited was founded in 1999 and is headquartered in Belo Horizonte, Brazil.

www.afya.com.br

Analyst Ratings

Consensus of 9 Wall Street analysts · sourced from Yahoo Finance

3.6Underperform

On a 1–5 scale: 1 = Strong Buy, 3 = Hold, 5 = Sell. Lower is more bullish.

12-Month Price Target

Low

$14.15

Average

$16.69

High

$20.49

The average target is +20.62% above the current price of $13.84.

Financial Results

Revenue, EBITDA and net profit (in USD) with net margin (net profit ÷ revenue).

Financial Health

Margins, leverage and cash-flow quality derived from Afya's income statement, balance sheet and cash flow (absolute figures in USD).

ProfitabilityLeverageGrowth

Overall: Financially Strong

Net Margin: 20.0%
ROE: 16.1%
Rev Growth (YoY): +3.97%
Net Debt / EBITDA: 1.11×
Current Ratio: 1.78×
Interest Coverage: —
Free Cash Flow: 1.17B
Payout Ratio: 36.1%

Income — Margins & Efficiency

Metric	Last 12MQ2'25 – Q1'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022	Δ	2021	Δ	2020	Δ	2019	Δ	2018	Δ	2017
Revenue	$725,723,482	+9.6%	$661,887,638	+23.7%	$534,862,817	-9.8%	$592,947,301	+34.5%	$440,725,315	+42.8%	$308,673,118	+33.4%	$231,405,944	+23.8%	$186,923,312	+116.9%	$86,194,569	+32.1%	$65,237,534
Gross profit	$466,649,840	+9.4%	$426,672,361	+26.2%	$338,096,441	-7.1%	$364,129,314	+30.9%	$278,073,080	+45.2%	$191,567,807	+29.7%	$147,671,118	+34.2%	$110,012,150	+156.9%	$42,817,356	+54.2%	$27,768,113
Operating income	$235,872,492	+8.6%	$217,189,615	+32.6%	$163,828,000	+3.6%	$158,150,386	+25.8%	$125,667,033	+58.8%	$79,152,454	+13.1%	$69,995,428	+36.9%	$51,111,995	+105.3%	$24,894,946	+67.1%	$14,902,298
EBITDA	$321,280,069	+31.5%	$244,296,134	+23.9%	$197,158,096	-13.5%	$227,905,860	+29.6%	$175,799,227	+62.3%	$108,314,064	+18.9%	$91,091,002	+15.9%	$78,581,352	+191.7%	$26,934,593	+69.3%	$15,906,194
Net profit	$145,451,380	+8.0%	$134,706,595	+31.8%	$102,220,819	+28.3%	$79,651,148	+12.7%	$70,690,118	+76.3%	$40,092,995	-28.7%	$56,267,397	+46.8%	$38,328,455	+72.0%	$22,289,247	+62.6%	$13,709,341
Gross margin	64.3%	-0.2 p.p.	64.5%	+1.3 p.p.	63.2%	+1.8 p.p.	61.4%	-1.7 p.p.	63.1%	+1.0 p.p.	62.1%	-1.8 p.p.	63.8%	+5.0 p.p.	58.9%	+9.2 p.p.	49.7%	+7.1 p.p.	42.6%
Operating margin	32.5%	-0.3 p.p.	32.8%	+2.2 p.p.	30.6%	+4.0 p.p.	26.7%	-1.8 p.p.	28.5%	+2.9 p.p.	25.6%	-4.6 p.p.	30.2%	+2.9 p.p.	27.3%	-1.5 p.p.	28.9%	+6.0 p.p.	22.8%
EBITDA margin	44.3%	+7.4 p.p.	36.9%	+0.0 p.p.	36.9%	-1.6 p.p.	38.4%	-1.5 p.p.	39.9%	+4.8 p.p.	35.1%	-4.3 p.p.	39.4%	-2.7 p.p.	42.0%	+10.8 p.p.	31.2%	+6.9 p.p.	24.4%
Net margin	20.0%	-0.3 p.p.	20.4%	+1.2 p.p.	19.1%	+5.7 p.p.	13.4%	-2.6 p.p.	16.0%	+3.1 p.p.	13.0%	-11.3 p.p.	24.3%	+3.8 p.p.	20.5%	-5.4 p.p.	25.9%	+4.8 p.p.	21.0%
Revenue growth (YoY)	4.0%	-5.7 p.p.	9.7%	-5.2 p.p.	14.9%	-8.6 p.p.	23.5%	-12.0 p.p.	35.5%	-7.7 p.p.	43.1%	-16.9 p.p.	60.0%	-64.8 p.p.	124.8%	+70.2 p.p.	54.6%	—	—
Effective tax rate	12.5%	+1.7 p.p.	10.7%	+6.7 p.p.	4.1%	-1.6 p.p.	5.6%	-2.7 p.p.	8.3%	-3.1 p.p.	11.4%	+3.3 p.p.	8.1%	+0.5 p.p.	7.6%	+3.5 p.p.	4.0%	-0.9 p.p.	4.9%
Interest coverage	—	—	—	—	2.77×	+31.0%	2.11×	-15.0%	2.48×	-2.8%	2.56×	-88.6%	22.33×	+46.8%	15.21×	-61.4%	39.40×	-15.3%	46.53×

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Balance Sheet — Health & Leverage

Metric	Last 12MQ2'25 – Q1'26	Δ	2025	Δ	2024	Δ	2023	Δ	2022	Δ	2021	Δ	2020	Δ	2019	Δ	2018	Δ	2017
Net debt	$355,453,732	-2.4%	$364,053,723	-0.6%	$366,221,855	-16.3%	$437,572,471	+42.6%	$306,838,739	+20.9%	$253,693,763	+1267.1%	$18,557,116	+112.5%	-$148,999,019	-3807.7%	$4,018,636	+161.4%	-$6,543,747
Net Debt / Equity	0.39×	-4.2%	0.41×	-22.4%	0.53×	-10.1%	0.59×	+16.3%	0.51×	+5.8%	0.48×	+1284.4%	0.03×	+111.9%	-0.29×	-1034.2%	0.03×	+106.6%	-0.47×
Net Debt / EBITDA	1.11×	-25.8%	1.49×	-19.8%	1.86×	-3.3%	1.92×	+10.0%	1.75×	-25.5%	2.34×	+1049.7%	0.20×	+110.7%	-1.90×	-1370.9%	0.15×	+136.3%	-0.41×
Debt / Equity	0.67×	+4.9%	0.64×	-13.5%	0.74×	+0.1%	0.74×	-12.5%	0.85×	+15.7%	0.73×	+78.7%	0.41×	+145.6%	0.17×	+7.7%	0.16×	+87.0%	0.08×
Current ratio	1.78×	-18.8%	2.20×	+57.6%	1.39×	+22.6%	1.14×	-37.1%	1.81×	+14.8%	1.57×	-34.0%	2.38×	-28.5%	3.34×	+355.7%	0.73×	-37.1%	1.16×
Return on equity (ROE)	16.1%	+0.9 p.p.	15.2%	+0.4 p.p.	14.8%	+4.1 p.p.	10.7%	-1.0 p.p.	11.7%	+4.1 p.p.	7.6%	-2.9 p.p.	10.5%	+3.0 p.p.	7.5%	-9.7 p.p.	17.2%	-81.2 p.p.	98.4%
Return on assets (ROA)	7.9%	+0.1 p.p.	7.9%	+0.7 p.p.	7.2%	+2.1 p.p.	5.1%	-0.1 p.p.	5.2%	+1.7 p.p.	3.5%	-2.6 p.p.	6.1%	+0.8 p.p.	5.3%	-4.1 p.p.	9.4%	-34.4 p.p.	43.8%
Book value / share	$10.01	+3.2%	$9.70	+28.0%	$7.58	-7.6%	$8.20	+21.9%	$6.73	+19.7%	$5.62	-1.7%	$5.72	-15.2%	$6.75	+356.7%	$1.48	+830.4%	$0.16

Newest column (“Last 12M”) = trailing 12 months, the last 4 reported quarters — shown with the quarter range it spans; earlier columns are full fiscal years.

Net Debt & Leverage

Free Cash Flow

Margins

Dividend Payout Ratio

Capex ÷ Revenue

Cash Conversion (operating cash flow ÷ net income)

Ratios computed from company financial statements. Net Debt = total debt − cash & equivalents; FCF = operating cash flow − capital expenditure; absolute values in USD.

Valuation & Dividends

P/E Ratio History

Dividend History

This year (YTD) $0.66/share · yield 4.74%

Dividends and yield from Yahoo Finance (per ADR share, in US dollars). The current-year figures are calendar year-to-date (dividends actually paid this year), not the trailing 12 months.

Frequently Asked Questions

Why hold Afya AFYA ADR instead of local B3 shares?

Buying directly on Brazil’s B3 exchange means opening a local brokerage account, converting currency and dealing with Brazilian tax paperwork. ADRs remove that friction: they settle in dollars, follow US market hours, and report in formats foreign investors already understand.

The trade-off is that an ADR’s price reflects two moving parts: (1) the underlying share price, quoted in reais on the B3, and (2) the USD/BRL exchange rate. Because of that second part, a rising company can still deliver a flat, or even negative, dollar return if the real weakens against the dollar. The same applies to ETFs: funds such as EWZ, EWZS and FLBR bundle dozens of these companies into a single ticker for instant diversification, but their dollar value still moves with the real.

Where is Afya listed?

Afya trades on a single exchange: NASDAQ in the United States (AFYA, US dollars). That is the line quoted on this page.

What is Afya's primary listing?

Afya's primary listing is on NASDAQ in the United States, where it trades as AFYA in US dollars — the line quoted on this page. It has no directly listed share on Brazil’s B3.

How can I buy Afya stock in the United States?

Afya is listed on the NASDAQ under AFYA, priced in US dollars. Any US brokerage offering NASDAQ-listed securities can trade it, with no foreign-account paperwork and no currency conversion.

As of Fri, Aug 14, 17:00 BRT · Market closed

Financial data last updated: August 15, 2026

← All stocks & ETFs